Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Foresight Diagnostics is not a typical SaaS or enterprise software product, but a cancer molecular diagnostics and clinical research services company, now a Natera company. Its core product, Foresight CLARITY™, is an ultra-sensitive ctDNA-MRD platform based on PhasED-Seq™, used to detect minimal residual disease at key treatment milestones and support cancer recurrence risk assessment, treatment response evaluation, and drug development.
The platform covers both B-cell lymphomas and solid tumors. The B-cell Lymphoma Platform uses a fixed panel for DLBCL/LBCL, follicular lymphoma, classic Hodgkin lymphoma, and more. The Solid Tumor Platform is a personalized assay, with the official website listing NSCLC, breast cancer, and other exploratory indications. On the services side, Foresight provides CDx companion diagnostic development, clinical trial execution, translational medicine research, study design, custom bioinformatics, and results interpretation, with centralized testing conducted through CLIA-certified/registered central laboratories.
The official website does not disclose pricing, packages, trials, or free version information, indicating that quotes are clearly project-based or partnership-based. Its target customers are mainly biopharmaceutical companies, academic research institutions, and clinical trial teams, rather than standard enterprise software buyers.
Its strengths lie in clear technical positioning and a relatively strong body of clinical research evidence: the website mentions more than 30 publications, over 25 academic and pharmaceutical partners, and reports study results showing relapse detection in large B-cell lymphoma approximately 200 days earlier than PET/CT. Its expert team spans liquid biopsy, clinical practice, regulatory affairs, and operations, making it suitable for complex drug development projects. The limitations are also clear: it is not a self-service SaaS product and lacks enterprise software information such as APIs, permissions, integrations, deployment, and SLAs. Some performance characteristics are also noted as not yet evaluated by the FDA, so clinical implementation should be assessed carefully in light of regulatory requirements and project boundaries.
It is suitable for pharmaceutical companies and research institutions that need to use MRD as an enrollment biomarker, surrogate endpoint, treatment response measure, or companion diagnostic pathway. The source text does not provide information on access from China, and because its services involve medical testing as well as cross-border sample and data compliance, domestic institutions should further confirm the feasibility of access, collaboration, and regulatory compliance.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on foresight-dx.com official site.
foresight-dx.com is an United States SaaS provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach foresight-dx.com directly.